Analytical Data
-
基因名
PA1
- Application
-
别名
PAGR1;C16orf53;PA1;PAXIP1-associated glutamate-rich Protein 1
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q9BTK6
-
表达区间
1-254aa
-
氨基酸序列
MSLARGHGDTAASTAAPLSEEGEVTSGLQALAVEDTGGPSASAGKAEDEGEGGREETEREGSGGEEAQGEVPSAGGEEPAEEDSEDWCVPCSDEEVELPADGQPWMPPPSEIQRLYELLAAHGTLELQAEILPRRPPTPEAQSEEERSDEEPEAKEEEEEKPHMPTEFDFDDEPVTPKDSLIDRRRTPGSSARSQKREARLDKVLSDMKRHKKLEEQILRTGRDLFSLDSEDPSPASPPLRSSGSSLFPRQRKY
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PA1, or Plasminogen Activator Inhibitor-1, is a crucial protein involved in the regulation of fibrinolysis and is part of the serine protease inhibitor (serpin) family. Its primary function is to inhibit tissue-type plasminogen activator (t-PA) and urokinase-type plasminogen activator (u-PA), thereby playing a significant role in the balance of clot formation and dissolution. Elevated levels of PA1 have been associated with various pathological conditions, including obesity, metabolic syndrome, cardiovascular diseases, and certain cancers, which makes it a critical factor in understanding thrombotic and hemorrhagic disorders. Research on PA1 recombinant proteins has important implications for developing therapeutic strategies aimed at modulating fibrinolytic pathways. The production of recombinant PA1 allows for detailed studies on its structure-function relationships, competitive inhibition mechanisms, and interactions with other components of the hemostatic system. Furthermore, recombinant PA1 serves as a potential biomarker in clinical settings for assessing the risk of thrombotic events and disease progression. Understanding the precise role of PA1 in various biological processes can pave the way for novel interventions, particularly in diseases characterized by dysregulated fibrinolysis, thus highlighting the significance of ongoing research in this area.
